基本情况

符立梧，中山大学肿瘤防治中心教授，博士生导师。

 

研究领域

抗癌药物药理学、毒理学、抗癌药物分子机理及实现肿瘤化疗个体化的研究、肿瘤干细胞抗药性的研究

 

教育背景

1993年9月至1996年7月 博士，中山医科大学

1990年9月至1993年7月 硕士，中山医科大学  

1982年9月至1987年7月 学士，广东医药学院

 

工作经历

2002年6月至今 教授，中山大学肿瘤防治中心 

2002年5月     副研究员，中山大学（原中山医科大学）肿瘤中心 

1998年11月    讲师，中山医科大学

1990年9月     助教，广东医药学院  

 

论文发表

1. Mai Z, Fu L*, Su J, To KKW, Yang C, Xia C*. Intra-tumoral sphingobacterium multivorum promotes triple-negative breast cancer progression by suppressing tumor immunosurveillance. Mol Cancer. 2025 Jan 8;24(1):6.

2. Liu X, To KKW, Zeng Q*, Fu L*. Effect of Extracellular Vesicles Derived From Tumor Cells on Immune Evasion. Adv Sci (Weinh). 2025 Feb 3:e2417357.

3. Li S#，Zhao X#，Fu K，Zhu S，Pan C，Yang C，Wang F，To KKW，Fu L*. Resistance to antibody–drug conjugates: A review. Acta Pharmaceutica Sinica B. 2024.12. DOI：10.1016/j.apsb.2024.12.036

4. Yang C, Wang X, To KKW, Cui C, Luo M, Wu S, Huang L, Fu K, Pan C, Liu Z, Fan T, Yang C, Wang F*, Fu L*. Circulating tumor cells shielded with extracellular vesicle-derived CD45 evade T cell attack to enable metastasis. Signal Transduct Target Ther. 2024 Apr 5;9(1):84.

5. Yang K#, Fu K#, Zhang H, Wang X, To KKW, Yang C, Wang F, Chen ZS, Fu L*. PBA2, a novel inhibitor of the beta-catenin/CBP pathway, eradicates chronic myeloid leukemia including BCR-ABL T315I mutation.  Mol Cancer. 2024 Sep 28;23(1):209.

6. Wang F#, Fu K#, Wang Y, Pan C, Wang X, Liu Z, Yang C, Zheng Y, Li X, Lu Y, To KKW*, Xia C*, Zhang J*, Shi Z*, Hu Z*, Huang M*, Fu L*. Small-molecule agents for cancer immunotherapy. Acta Pharm Sin B. 2024 Mar;14(3):905-952.

7. To KKW, Huang Z, Zhang H, Ashby CR Jr, Fu L*. Utilizing non-coding RNA-mediated regulation of ATP binding cassette (ABC) transporters to overcome multidrug resistance to cancer chemotherapy. Drug Resist Updat. 2024 Mar;73:101058.

8. Yang Q, To KKW, Hu G, Fu K, Yang C, Zhu S, Pan C, Wang F, Luo K*, Fu L*. BI-2865, a pan-KRAS inhibitor, reverses the P-glycoprotein induced multidrug resistance in vitro and in vivo. Cell Commun Signal. 2024 Jun 13;22(1):325.

9. Pan C, Wang X, Yang C, Fu K, Wang F, Fu L*. The culture and application of circulating tumor cell-derived organoids. Trends Cell Biol. 2024 Nov 9:S0962-8924(24)00210-1.

10. Luo M, Wang X, Wu S, Yang C, Su Q, Huang L, Fu K, An S, Xie F, To KKW, Wang F*, Fu L*. A20 promotes colorectal cancer immune evasion by upregulating STC1 expression to block "eat-me" signal. Signal Transduct Target Ther. 2023 Aug 23;8(1):312.

11. Mai Y, Su J, Yang C, Xia C*, Fu L*. The strategies to cure cancer patients by  eradicating cancer stem-like cells. Mol Cancer. 2023 Oct 18;22(1):171.

12. Xia C*, Yin S, To KKW, Fu L*. CD39/CD73/A2AR pathway and cancer immunotherapy. Mol Cancer. 2023 Mar 2;22(1):44.

13. Fan J, To KKW, Chen ZS*, Fu L*. ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance. Drug Resist Updat. 2023 Jan;66:100905.

14. Xia C, Su J, Liu C, Mai Z, Yin S, Yang C, Fu L*. Human microbiomes in cancer development and therapy. MedComm (2020). 2023 Feb 26;4(2):e221.

15. Huang L, Wang F, Wang X, Su C, Wu S, Yang C, Luo M, Zhang J, Fu L*. M2-like macrophage-derived exosomes facilitate metastasis in non-small-cell lung cancer by delivering integrin αVβ3. MedComm.  2023 Feb; 4(1): e191.

16. Wang X, Guo Z, Wu X, Chen D, Wang F, Yang L, Luo M, Wu S, Yang C, Huang L, Fu L*. Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer.  Immunotargets Ther. 2023 Jan 4;12:1-16.

17. Xu L, Huang J, Liu J, et al. CM082 enhances the efficacy of chemotherapeutic drugs by inhibiting the drug efflux function of ABCG2[J]. Molecular Therapy-Oncolytics, 2020, 16: 100-110.